Thomas Cannell, DVM

President & Chief Executive Officer

Thomas Cannell serves as president and chief executive officer of Sesen Bio. Prior to joining Sesen Bio, Dr. Cannell served as chief operating officer and president of global commercial products at Orexigen Therapeutics, Inc., where he led the successful commercialization and profitability of Contrave®. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co.,Inc., where he held senior leadership positions in global commercialization, consumer marketing,and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as president of Merck Canada and head of marketing and strategy for Merck Sharp & Dohme Corp., Japan, a subsidiary of Merck & Co.,where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University.

Gregory P. Adams, Ph.D.

Chief Scientific Officer

Gregory P. Adams, Ph.D., serves as our chief scientific officer, leading the advancement of the company’s oncology pipeline of novel next-generation antibody-drug conjugates. Previously, Dr. Adams was director of biological research and therapeutics at Fox Chase Cancer Center from 2013 to 2015, where he led a laboratory group focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Earlier at Fox Chase Cancer Center, Dr. Adams co-lead the Center’s Developmental Therapeutics Program from 2009 to 2013. Dr. Adams serves on the editorial boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals. He is a member of the Integration Panel of the U.S. Department of Defense’s Breast Cancer Research Program and recently completed a four-year term as a member of the U.S. National Cancer Institute’s Cancer Immunopathology and Immunotherapy Study Section. He was a co-founder of a computational antibody design company, RAbD Biotech, and has served on the scientific advisory boards of a number of biotechnology companies including Endo Pharmaceuticals Inc., Symphogen A/S, Avipep Pty. Ltd., AvidBiologics (now known as Formation Biologics, Inc.) and YM Biosciences Inc. (which was acquired by Gilead Sciences, Inc.). He graduated from the University of California, Santa Cruz with a bachelor’s degree in biology in 1983 and earned a Ph.D. in immunology from the University of California at Davis in 1991.

Dennis Kim, M.D., MPH

Chief Medical Officer

Dennis Kim, M.D., MPH, has served as Sesen Bio’s chief medical officer since December 2018. Dr. Kim has significant drug development and commercialization experience, having played key roles in both the approval and commercial launch of more than 10 products in oncology and immunology. Prior to joining Sesen Bio, Dr. Kim held senior and leadership roles at Ipsen, Spectrum, Novartis, Biogen Idec, and Amgen. Previously, Dr. Kim was an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention where he played active roles in environmental and infectious disease studies. Dr. Kim earned his bachelor’s degree in chemistry and biology from Harvard, his M.D. from Stanford University and his MPH from the University of California, Los Angeles.

Glen MacDonald, Ph.D.

Chief Technology Officer

Glen C. MacDonald, Ph.D., serves as our chief technology officer. Previously, Dr. MacDonald served our predecessor company in several research related capacities from 1997 to 2005. Prior to joining us, Dr. MacDonald held a Manitoba Cancer Treatment Research Foundation Fellowship from 1996 to 1997 while serving as a post-doctoral fellow at the University of Manitoba Cancer Treatment Research Foundation from 1995 to 1997. Dr. MacDonald also served as a Canadian Arthritis Society post-doctoral fellow at the University of North Carolina at Chapel Hill from 1993 to 1995. He graduated from the University of Guelph with a bachelor’s degree in genetics in 1980 and earned an M.Sc. and Ph.D. from the University of Manitoba in 1987 and 1993, respectively. Dr. MacDonald’s scientific background is extensive, having published in the areas of monoclonal antibodies, graft versus-host disease, lupus and apoptosis.

Richard F. Fitzgerald

Chief Financial Officer

Richard F. Fitzgerald has served as Sesen Bio’s chief financial officer since October 2017. From July 2017 through October 2017, he served as a consultant to private life science based companies. Previously he served as the chief financial officer of PAVmed Inc. (Nasdaq:PAVM) from October 2015 through March 2017 during which time PAVmed completed its IPO and Nasdaq listing. From April 2009 to October 2015, Mr. Fitzgerald was the chief financial officer of TechPrecision Inc. (OTCBB: TPCS), a global manufacturer of precision large-scale components for the medical device, defense and energy industries. From 2002 to 2008, he served in various senior financial roles culminating in the role of vice president and chief financial officer of Nucleonics Inc., a venture-backed biotechnology company and early pioneer within the field of RNAi therapeutics whose assets were sold to Alnylam Pharmaceuticals Inc. (Nasdaq:ALNY) in December 2008. During his tenure at Nucleonics, he served as co-chair of the Biotechnology Industry Organization’s (BIO) National CFO and Tax VP Committee, supporting federal tax, finance and capital formation lobbying efforts, and was active in the Association of Biotechnology Financial Officers. From 1995 to 2002, Mr. Fitzgerald served in the corporate development office and, from 1998 to 2002, as director of corporate development for Exelon Corporation (NYSE:EXC), an energy generator and distributor, where he managed business development efforts, mergers and acquisitions, including the $18 billion merger with Unicom and the rollup of utility contractors which led to the formation of InfraSource (NYSE: IFS). From 1985 to 1995, Mr. Fitzgerald served as a senior manager in the Audit and Transaction Services Group of Coopers & Lybrand LLP (now PricewaterhouseCoopers). He is a member of the American and Pennsylvania Institutes of Public Accounting and a founding member of the Bucknell University Business Advisory Board. Mr. Fitzgerald received his B.S. in business administration and accounting from Bucknell University.

Mark R. Sullivan

General Counsel

Mark R. Sullivan brings more than 20 years of legal experience to his role as our acting general counsel.  Before joining Sesen Bio in April 2018, he provided outsourced in-house counsel services to companies in the life sciences and healthcare industries, including Sandoz Inc. and Bayer Healthcare. Prior to that, Mr. Sullivan served as the general counsel, chief compliance officer and secretary of MModal Inc., a public healthcare IT company for 9 years, until the company was taken private by One Equity Partners in July 2012.  At MModal, Mr. Sullivan was responsible for all securities, intellectual property, corporate governance, mergers and acquisitions, contracting and risk management matters, and he implemented and managed a formal compliance program for over 14,000 employees.  Prior to MModal, Mr. Sullivan was an attorney at the law firms of Pepper Hamilton LLP and Drinker Biddle & Reath LLP, where his practice focused on corporate and securities matters. Mr. Sullivan holds a J.D. from Rutgers University School of Law and a Bachelor of Arts from the University of Pennsylvania.

Madhu Anant M.Sc., Ph.D., RAC

Vice President, Regulatory Affairs

Madhu Anant brings more than 35 years of experience to her role as vice president of regulatory affairs at Sesen Bio. Prior to joining Sesen Bio, she served as the vice president, global regulatory affairs, hospital products for Mallinckrodt Pharmaceuticals where she was responsible for all regulatory activities including, strategy, health authority liaisons and regulatory pathways for development of products. Prior to Mallinckrodt, Madhu served as an independent consultant in numerous roles including, head of regulatory affairs and lead strategist in regulatory affairs, clinical development and medical affairs. Earlier, she served as director, global regulatory sciences, geographic optimization for Bristol-Myers Squibb. There, she led the global regulatory strategies for geographic optimization of mature brands in the cardiovascular, metabolic, anti-infective and oncology therapeutic areas. Madhu earned her Ph.D. from the International University for Professional Studies and her M.Sc. from the Institute of Science in Nagpur, India.